Lupin gets USFDA nod to market generic drug
Drug maker Lupin on Friday said it has received approval from the US health regulator to market a generic product, used in the treatment of a lung disease, in the American market.
Drug maker Lupin on Friday said it has received approval from the US health regulator to market a generic product, used in the treatment of a lung disease, in the American market. The company has received approval from the US Food and Drug Administration (USFDA) to market Pirfenidone tablets in strengths of 267 mg and 801 mg, the Mumbai-based drug maker said in a statement.
The company's product is the generic equivalent of La Roche Inc's Esbriet tablets, it added.
Also Read: Anil Agarwal says mulling separate listing of different businesses
Pirfenidone is used for the treatment of idiopathic pulmonary fibrosis.
As per IQVIA MAT data, Pirfenidone tablets had estimated annual sales of USD 218 million in the US.
Catch latest stock market updates here. For all other news related to business, politics, tech, sports and auto, visit Zeebiz.com.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.